PLoS ONE (Jan 2014)

PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.

  • Xusheng Bai,
  • Enke Zhang,
  • Hua Ye,
  • Vijayalakshmi Nandakumar,
  • Zhuo Wang,
  • Lihong Chen,
  • Chuanning Tang,
  • Jianhui Li,
  • Huijin Li,
  • Wei Zhang,
  • Wei Han,
  • Feng Lou,
  • Dandan Zhang,
  • Hong Sun,
  • Haichao Dong,
  • Guangchun Zhang,
  • Zhiyuan Liu,
  • Zhishou Dong,
  • Baishuai Guo,
  • He Yan,
  • Chaowei Yan,
  • Lu Wang,
  • Ziyi Su,
  • Yangyang Li,
  • Lindsey Jones,
  • Xue F Huang,
  • Si-Yi Chen,
  • Jinglong Gao

DOI
https://doi.org/10.1371/journal.pone.0099306
Journal volume & issue
Vol. 9, no. 6
p. e99306

Abstract

Read online

Breast cancer is the most common malignancy and the leading cause of cancer deaths in women worldwide. While specific genetic mutations have been linked to 5-10% of breast cancer cases, other environmental and epigenetic factors influence the development and progression of the cancer. Since unique mutations patterns have been observed in individual cancer samples, identification and characterization of the distinctive breast cancer molecular profile is needed to develop more effective target therapies. Until recently, identifying genetic cancer mutations via personalized DNA sequencing was impractical and expensive. The recent technological advancements in next-generation DNA sequencing, such as the semiconductor-based Ion Torrent sequencing platform, has made DNA sequencing cost and time effective with more reliable results. Using the Ion Torrent Ampliseq Cancer Panel, we sequenced 737 loci from 45 cancer-related genes to identify genetic mutations in 105 human breast cancer samples. The sequencing analysis revealed missense mutations in PIK3CA, and TP53 genes in the breast cancer samples of various histologic types. Thus, this study demonstrates the necessity of sequencing individual human cancers in order to develop personalized drugs or combination therapies to effectively target individual, breast cancer-specific mutations.